BioSpace News Archive

MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that dosing has commenced in a Phase 1b single-ascending dose patient study of its investigational drug candidate MYK-491.

Two of Amgen’s executive vice presidents are leaving the company.

Tonix Pharmaceuticals is halting its Phase III clinical trial of Tonmya in military related posttraumatic stress disorder (PTSD).

European Committee recommends Alnylam’s drug be approved for adults with stage 1 or stage 2 polyneuropathy.

For the first time, Merck’s Keytruda beat out Bristol-Myers Squibb’s Opdivo in sales.

Medivir AB announces positive top-line joint structure outcomes from the MIV-711 osteoarthritis phase IIa extension study (MIV-711-202).

Elekta announced that it has acquired the Canadian quality assurance (QA) company Acumyn

On Thursday, July 26, 2018, the NASDAQ Composite closed the trading session at 7,852.18, down 1.01%; the Dow Jones Industrial Average edged 0.44% higher, to finish at 25,527.07; and the S&P 500 closed at 2,837.44, slightly dropping 0.30%.

Organised by UBM EMEA in collaboration with the China Chamber of Commerce for Import & Export of Medicines & Health Products and co-organised by Shanghai UBM Sinoexpo International Exhibition Co, CPhI and its co-located events -- ICSE, NEX, BioPh China, P-MEC, InnoPack and LABWorld China -- came to a successful conclusion at Shanghai New International Expo Centre on June 22.

ICON PLC, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today confirmed, that Dr. Ronan Lambe retired as a non-executive director at the Annual General Meeting (AGM) of the Company on the 24th July 2018.